Correlation Between Bavarian Nordic and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Bavarian Nordic and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bavarian Nordic and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bavarian Nordic AS and Monopar Therapeutics, you can compare the effects of market volatilities on Bavarian Nordic and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bavarian Nordic with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bavarian Nordic and Monopar Therapeutics.
Diversification Opportunities for Bavarian Nordic and Monopar Therapeutics
-0.41 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Bavarian and Monopar is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Bavarian Nordic AS and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Bavarian Nordic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bavarian Nordic AS are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Bavarian Nordic i.e., Bavarian Nordic and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Bavarian Nordic and Monopar Therapeutics
Assuming the 90 days horizon Bavarian Nordic AS is expected to under-perform the Monopar Therapeutics. But the pink sheet apears to be less risky and, when comparing its historical volatility, Bavarian Nordic AS is 3.67 times less risky than Monopar Therapeutics. The pink sheet trades about -0.05 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest 2,400 in Monopar Therapeutics on December 23, 2024 and sell it today you would earn a total of 1,600 from holding Monopar Therapeutics or generate 66.67% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Bavarian Nordic AS vs. Monopar Therapeutics
Performance |
Timeline |
Bavarian Nordic AS |
Monopar Therapeutics |
Bavarian Nordic and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Bavarian Nordic and Monopar Therapeutics
The main advantage of trading using opposite Bavarian Nordic and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bavarian Nordic position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.Bavarian Nordic vs. Mineralys Therapeutics, Common | Bavarian Nordic vs. Anebulo Pharmaceuticals | Bavarian Nordic vs. Bioatla | Bavarian Nordic vs. Bicycle Therapeutics |
Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Complementary Tools
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies |